Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Change in Accured Expenses (2016 - 2025)

Jaguar Health (JAGX) has disclosed Change in Accured Expenses for 11 consecutive years, with $528000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 270.87% to $528000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $913000.0, a 69.7% increase, with the full-year FY2024 number at -$1.1 million, up 61.73% from a year prior.
  • Change in Accured Expenses was $528000.0 for Q3 2025 at Jaguar Health, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q1 2022 to a low of -$6.7 million in Q3 2023.
  • A 5-year average of $36684.2 and a median of $141000.0 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1117.28% in 2021, then crashed 5724.0% in 2022.
  • Jaguar Health's Change in Accured Expenses stood at $1.0 million in 2021, then plummeted by 281.01% to -$1.9 million in 2022, then skyrocketed by 125.32% to $473000.0 in 2023, then tumbled by 352.85% to -$1.2 million in 2024, then soared by 144.15% to $528000.0 in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Change in Accured Expenses are $528000.0 (Q3 2025), $1.4 million (Q2 2025), and $141000.0 (Q1 2025).